Has Stuart Katchis, MD received payments from drug or device companies?

Yes. Drug and device makers reported $636,508 in general payments to Stuart Katchis, MD across 135 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Stuart Katchis, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Stuart Katchis, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Stuart Katchis, MD

Orthopaedic Surgery · New York, NYNPI 1366638439

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $465,611 of the $636,508 with a category attached, or 73.2%. 21 manufacturers reported payments, led by Medartis Inc. at 52.0% of the total. Reporting peaked in 2022 at $269,177 and has fallen 98.8% since, to $3,178 in 2025. Among orthopaedic surgery clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$636,508in general payments, 2019–2025

Across 135 payments — averaging $4714.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medartis Inc.$331K
Nextremity Solutions Inc.$268K
Zimmer Biomet$35K
Stryker$417
Treace Medical Concepts, Inc.$136
Johnson & Johnson$134
plus $1K from 15 others

What the payments were for

Royalty or licence$465,61173%
Consulting fees$156,81525%
Travel & lodging$10,0212%
Food & beverage$3,8041%
Gifts$2560%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medartis Inc.	24	$331,144
Nextremity Solutions Inc.	34	$268,445
Zimmer Biomet	34	$35,199
Stryker(2 entities)	9	$417
Treace Medical Concepts, Inc.	4	$136
Johnson & Johnson	3	$134
Terumo BCT, Inc.	1	$134
Sanara Medtech Inc.	2	$122
Baxter Healthcare	5	$118
Abbott	2	$113
Arteriocyte Medical Systems, Inc.	2	$87
Suvon Surgical LLC	2	$82
Trilliant Surgical LLC.	1	$73
Paragon 28, Inc.	2	$64
Heron Therapeutics, Inc.	3	$56
Bioventus LLC	2	$54
DJO, LLC	1	$45
KCI USA, Inc.	1	$28
Acell, Inc.	1	$24
Ferring Pharmaceuticals Inc.	1	$18
Smith+Nephew	1	$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

APTUS$331,119
Nextremity Nextra Hammertoe$13,923
Nextremity MSP$13,923
Nextremity ArcusTM$13,923
Lapidus Plate$10,767
Stratum$6,675
Nextremity ReLine$6,625
InCore Lapidus$2,000
Stratum Foot Plating System$1,105
Affixus$247
Bone Marrow Aspirate Concentrate System$134
CellerateRx$103
CARTIVA$100

How this compares

$636,508 in reported general payments places this provider in the 95th percentile of 1,079 orthopaedic surgery providers in New York.

See all orthopaedic surgery providers in New York →

Medicare billing

Part B allowed, 2024

$242,385

Medicare patients

519

Services billed

2,703

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Lidocaine	15	$444
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen	60	$319
Methylprednisolone	30	$233
Meloxicam	67	$223
Diclofenac Sodium	27	$207
Cephalexin	16	$136

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in New York

Anthony RomeoNew York$26.8M
Lawrence LenkeNew York$26.8M
Edwin SuNew York$13.2M
William RicciNew York$11.6M
Steven HaasNew York$11.3M
Giles ScuderiNew York$10.7M
Joseph ZuckermanNew York$9.9M
Evan FlatowNew York$9.6M
Bradford ParsonsNew York$9.4M
Geoffrey WestrichNew York$7.1M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →